N/A N=14 Treatment

Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory

Mild Cognitive Impairment

Bottom Line

View on ClinicalTrials.gov: NCT04646499 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2023

Primary outcome: Primary: Side Effects — 0.53 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Transcranial alternating current stimulation (Device)
Age: Adult, Older Adult · 55+ yrs
Sex: All
Sponsor: University of California, San Francisco
Primary completion: Dec 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Side Effects	0.53	—
PRIMARY Drop Out	1	—
SECONDARY Beta Amyloid Load Change	0.0008	0.34
SECONDARY Memory: Recall Change	1.5	0.024 sig
SECONDARY Memory: Paired Associates Change	11.5	0.083
SECONDARY Memory: Fluency Change	1.5	0.049 sig
SECONDARY Change in Tau	0.27	0.31

Summary

This project assessed the feasibility of transcranial alternating current stimulation in the gamma band to lower beta-amyloid load and improve memory performance.

Eligibility Criteria

Inclusion Criteria

English speaking
Grade 12 or more education
Normal or corrected to normal vision and hearing
Ability to complete cognitive tasks
Ability to cooperate and comply with all study procedures
Ability to tolerate tACS
Self-reported memory complaint
Diagnosed with mild cognitive impairment
Amyloid positive

Exclusion Criteria

Neurological or psychiatric disorders other than mild cognitive impairment
Receiving investigational medications or have participated in a trial with investigational medications within last 30 days
Family history of epilepsy
Implanted electronic devices (e.g., pacemaker)
Prior head trauma
Pregnant
IQ < 80
Taking cholinesterase inhibitory, memantine, or psychotropic medication
Taking anti-depressants or anti-anxiety medication
Color blind
Substance abuse
Glaucoma
Macular degeneration
Amblyopia (lazy eye)
Strabismus (crossed eyes)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04646499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.